Fuller H B CO 8-K filings

H.B. Fuller Company announced an amendment to its Second Amended and Restated Credit Agreement, extending the maturity date and adjusting interest rate margins.

H.B. Fuller Company has launched a recommended cash offer to acquire Advanced Medical Solutions Group plc to expand its medical adhesives portfolio and increase its total addressable market by $15 billion.

H.B. Fuller reported strong second-quarter 2026 results with a 19% increase in adjusted EPS and record operating cash flow, leading to an upward revision of full-year guidance.

H.B. Fuller Company shareholders successfully elected three directors and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

H.B. Fuller Company reported stronger-than-expected first-quarter adjusted earnings and EBITDA, leading to an increase in its full-year 2026 financial guidance.

H.B. Fuller Company announced robust fourth quarter and fiscal year 2025 results, highlighted by double-digit adjusted EPS growth and expanded adjusted EBITDA margins, despite a challenging economic environment.

H.B. Fuller strengthens its Board of Directors with the appointment of Celine Martin, a seasoned medical device executive, to support growth in high-margin medical markets.

H.B. Fuller Company reported robust third-quarter results with double-digit adjusted EPS growth and significant margin expansion, while tightening its full-year guidance due to a subdued global economic backdrop.

H.B. Fuller Company reported robust second-quarter 2025 financial results, showcasing a 5% year-on-year increase in adjusted EPS and EBITDA, prompting an upward revision of its full-year adjusted financial outlook.

H.B. Fuller held its 2025 Annual Meeting of Shareholders, where key proposals including the election of directors and executive compensation were approved.

H.B. Fuller's first quarter 2025 results show a decrease in net revenue but an increase in organic revenue, with adjusted EBITDA down due to higher raw material costs and variable compensation.

H.B. Fuller restated its historical financial information to reflect a change in operating segments, effective in the first quarter of fiscal year 2025.

H.B. Fuller's fourth quarter results were impacted by unfavorable raw material costs and delayed price realization, despite full year adjusted EBITDA margin expansion.

H.B. Fuller released preliminary fiscal year 2024 results, indicating lower than expected revenue and adjusted EBITDA, and announced an upcoming investor conference call.

H.B. Fuller Company's Executive Vice President of Engineering Adhesives, Zhiwei Cai, has announced his retirement, effective March 1, 2025.

H.B. Fuller has appointed Teresa Rasmussen as the new Chair of the Board, succeeding Lee Mitau who is retiring after years of service.

H.B. Fuller's Executive Vice President and Chief Administrative Officer, Traci L. Jensen, has announced her retirement, effective November 30, 2024.

H.B. Fuller announced a 7% year-on-year increase in adjusted earnings per share for the third quarter of 2024, alongside a 6% rise in adjusted EBITDA.

H.B. Fuller reported a strong second quarter with adjusted EPS up 20% year-on-year and has updated its full-year adjusted EBITDA guidance to the upper end of the previously provided range.

H.B. Fuller Company held its 2024 Annual Meeting of Shareholders, electing three directors, ratifying the appointment of Ernst & Young LLP as its auditor, and approving executive compensation.

H.B. Fuller's first quarter results show a 22% year-on-year increase in adjusted EPS, driven by strong operating income growth and margin expansion.

H.B. Fuller Company has entered into a refinancing and incremental amendment, securing $994 million in term loans and reducing interest rate margins.

H.B. Fuller has modified its short-term incentive plan for executives, adding EBITDA margin as a key metric and increasing CEO Celeste Mastin's base salary and stock-based awards.

H.B. Fuller reported strong fourth quarter and fiscal year 2023 results, highlighted by record adjusted EBITDA margins and significant cash flow improvement despite a revenue decrease.